Novel mutation in ATP13A2 widens the spectrum of Kufor-Rakeb syndrome (PARK9)

被引:42
作者
Eiberg, H. [1 ]
Hansen, L. [1 ]
Korbo, L. [2 ]
Nielsen, I. M. [1 ]
Svenstrup, K. [1 ,3 ]
Bech, S. [1 ,2 ]
Pinborg, L. H. [4 ,5 ]
Friberg, L. [6 ]
Hjermind, L. E. [1 ,2 ]
Olsen, O. R. [7 ]
Nielsen, J. E. [1 ,2 ]
机构
[1] Univ Copenhagen, Dept Cellular & Mol Med, Fac Hlth, DK-2200 Copenhagen N, Denmark
[2] Univ Copenhagen Hosp, Bispebjerg Hosp, Dept Neurol, DK-2100 Copenhagen, Denmark
[3] Rigshosp, Neurogenet Clin, Memory Disorders Res Grp, DK-2100 Copenhagen, Denmark
[4] Rigshosp, Dept Neurol, NRU, DK-2100 Copenhagen, Denmark
[5] Rigshosp, Dept Neurol, Epilepsy Clin, DK-2100 Copenhagen, Denmark
[6] Univ Copenhagen Hosp, Bispebjerg Hosp, Dept Nucl Med, DK-2100 Copenhagen, Denmark
[7] Med Ctr Middle Greenland Hlth Reg, Sisimiut, Greenland
关键词
ataxia; ATP13A2; frame-shift mutation; inuit; Kufor-Rakeb syndrome; neuropathy; PARK9; PALLIDO-PYRAMIDAL DEGENERATION; SUPRANUCLEAR UPGAZE PARESIS; RESPONSIVE PARKINSONISM; DISEASE; DEMENTIA; VARIANT; NEURODEGENERATION;
D O I
10.1111/j.1399-0004.2011.01745.x
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Kufor-Rakeb syndrome (KRS) is a rare autosomal recessive inherited juvenile parkinsonian syndrome caused by mutations in ATP13A2. We describe six patients from a consanguineous Greenlandic Inuit family, homozygous for a novel frame-shift mutation in exon 22 of ATP13A2 (c.2473C>AA, p.Leu825AsnfsX32). Disease onset varied from 10 to 29 years of age, the latest reported, and the clinical features were highly variable within a wide spectrum of an extrapyramidal-pyramidal syndrome with cognitive/psychiatric features. Ataxia was seen in two patients and axonal neuropathy in one, features not previously related to KRS. Dopamine transporter scans showed symmetrical, severely reduced uptake in striatum in two patients. Magnetic resonance imaging was without atrophy in one patient despite disease duration of 17 years, and cerebral and cerebellar atrophy was seen in another patient after 4 years of disease duration. The molecular pathogenic mechanisms of ATP13A2 mutations are discussed. The observation that the mutant transcript is not degraded by nonsense-mediated RNA decay and the fact that none of the eight heterozygous carriers from the family have KRS symptoms suggest that the mutant protein does not interfere and destroy the function of the wild-type ATP13A2 protein.
引用
收藏
页码:256 / 263
页数:8
相关论文
共 25 条
  • [1] ALDIN ASN, 1994, ACTA NEUROL SCAND, V89, P347
  • [2] Anjum I, 2010, MOL VIS, V16, P549
  • [3] Recessively Inherited Parkinsonism Effect of ATP13A2 Mutations on the Clinical and Neuroimaging Phenotype
    Brueggemann, Norbert
    Hagenah, Johann
    Reetz, Kathrin
    Schmidt, Alexander
    Kasten, Meike
    Buchmann, Inga
    Eckerle, Susanne
    Baehre, Manfred
    Muenchau, Alexander
    Djarmati, Ana
    van der Vegt, Joyce
    Siebner, Hartwig
    Binkofski, Ferdinand
    Ramirez, Alfredo
    Behrens, Maria I.
    Klein, Christine
    [J]. ARCHIVES OF NEUROLOGY, 2010, 67 (11) : 1357 - 1363
  • [4] ATP13A2-Related Neurodegeneration (PARK9) Without Evidence of Brain Iron Accumulation
    Chien, Hsin Fen
    Bonifati, Vincenzo
    Barbosa, Egberto Reis
    [J]. MOVEMENT DISORDERS, 2011, 26 (07) : 1364 - 1365
  • [5] Juvenile dystonia-parkinsonism and dementia caused by a novel ATP13A2 frameshift mutation
    Crosiers, David
    Ceulemans, Berten
    Meeus, Bram
    Nuytemans, Karen
    Pals, Philippe
    Van Broeckhoven, Christine
    Cras, Patrick
    Theuns, Jessie
    [J]. PARKINSONISM & RELATED DISORDERS, 2011, 17 (02) : 135 - 138
  • [6] ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease
    Di Fonzo, A.
    Chien, H. F.
    Socal, M.
    Giraudo, S.
    Tassorelli, C.
    Iliceto, G.
    Fabbrini, G.
    Marconi, R.
    Fincati, E.
    Abbruzzese, G.
    Marini, P.
    Squitieri, F.
    Horstink, M. W.
    Montagna, P.
    Dalla Libera, A.
    Stocchi, F.
    Goldwurm, S.
    Ferreira, J. J.
    Meco, G.
    Martignoni, E.
    Lopiano, L.
    Jardim, L. B.
    Oostra, B. A.
    Barbosa, E. R.
    Bonifati, V.
    [J]. NEUROLOGY, 2007, 68 (19) : 1557 - 1562
  • [7] ATP13A2 Variants in Early-Onset Parkinson's Disease Patients and Controls
    Djarmati, Ana
    Hagenah, Johann
    Reetz, Kathrin
    Winkler, Susen
    Behrens, Maria Isabel
    Pawlack, Heike
    Lohmann, Katja
    Ramirez, Alfredo
    Tadic, Vera
    Brueggemann, Norbert
    Berg, Daniela
    Siebner, Hartwig R.
    Lang, Anthony E.
    Pramstaller, Peter P.
    Binkofski, Ferdinand
    Kostic, Vladimir S.
    Volkmann, Jens
    Gasser, Thomas
    Klein, Christine
    [J]. MOVEMENT DISORDERS, 2009, 24 (14) : 2104 - 2111
  • [8] Lack of association between ATP13A2 Ala746Thr variant and Parkinson's disease in Han population of mainland China
    Fei, Qing-Zhou
    Cao, Li
    Xiao, Qin
    Zhang, Ting
    Zheng, Lan
    Wang, Xi-Jin
    Wang, Gang
    Zhou, Hai-Yan
    Wang, Ying
    Chen, Sheng-Di
    [J]. NEUROSCIENCE LETTERS, 2010, 475 (02) : 61 - 63
  • [9] Juvenile parkinsonism associated with heterozygous frameshift ATP13A2 gene mutation
    Fong, Choong Yi
    Rolfs, Arndt
    Schwarzbraun, Thomas
    Klein, Christine
    O'Callaghan, Finbar J. K.
    [J]. EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2011, 15 (03) : 271 - 275
  • [10] Rapid Screening of ATP13A2 Variant with High-Resolution Melting Analysis
    Funayama, Manabu
    Tomiyama, Hiroyuki
    Wu, Ruey-Meei
    Ogaki, Kotaro
    Yoshino, Hiroyo
    Mizuno, Yoshikuni
    Hattori, Nobutaka
    [J]. MOVEMENT DISORDERS, 2010, 25 (14) : 2434 - 2437